{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:48:44Z","timestamp":1785883724838,"version":"3.56.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41440-026-02697-3","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T07:03:32Z","timestamp":1780988612000},"page":"2399-2403","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The blood pressure\u2013lowering effect of an anti-soluble epoxide hydrolase vaccine in angiotensin II\u2013induced hypertension in mice"],"prefix":"10.1038","volume":"49","author":[{"given":"Shigeki","family":"Shichida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Shiraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Nakagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Node","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"2697_CR1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1152\/physrev.00021.2011","volume":"92","author":"JD Imig","year":"2012","unstructured":"Imig JD. Epoxides and soluble epoxide hydrolase in cardiovascular physiology. Physiol Rev. 2012;92:101\u201330. https:\/\/doi.org\/10.1152\/physrev.00021.2011.","journal-title":"Physiol Rev"},{"key":"2697_CR2","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1126\/science.285.5431.1276","volume":"285","author":"K Node","year":"1999","unstructured":"Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science. 1999;285:1276\u20139. https:\/\/doi.org\/10.1126\/science.285.5431.1276.","journal-title":"Science"},{"key":"2697_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.tips.2006.11.002","volume":"28","author":"BT Larsen","year":"2007","unstructured":"Larsen BT, Campbell WB, Gutterman DD. Beyond vasodilatation: non-vasomotor roles of epoxyeicosatrienoic acids in the cardiovascular system. Trends Pharmacol Sci. 2007;28:32\u20138. https:\/\/doi.org\/10.1016\/j.tips.2006.11.002.","journal-title":"Trends Pharmacol Sci"},{"key":"2697_CR4","doi-asserted-by":"publisher","first-page":"10714","DOI":"10.3390\/ijms221910714","volume":"22","author":"XX Guan","year":"2021","unstructured":"Guan XX, Rao DN, Liu YZ, Zhou Y, Yang HH. Epoxyeicosatrienoic Acids and Fibrosis: Recent Insights for the Novel Therapeutic Strategies. Int J Mol Sci. 2021;22:10714 https:\/\/doi.org\/10.3390\/ijms221910714.","journal-title":"Int J Mol Sci"},{"key":"2697_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.642470","volume":"12","author":"J Lai","year":"2021","unstructured":"Lai J, Chen C. The Role of Epoxyeicosatrienoic Acids in Cardiac Remodeling. Front Physiol. 2021;12:642470. https:\/\/doi.org\/10.3389\/fphys.2021.642470.","journal-title":"Front Physiol"},{"key":"2697_CR6","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/nrd2875","volume":"8","author":"JD Imig","year":"2009","unstructured":"Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov. 2009;8:794\u2013805. https:\/\/doi.org\/10.1038\/nrd2875.","journal-title":"Nat Rev Drug Discov"},{"key":"2697_CR7","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1111\/bcp.12855","volume":"81","author":"AL Lazaar","year":"2016","unstructured":"Lazaar AL, Yang L, Boardley RL, Goyal NS, Robertson J, Baldwin SJ, et al. Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor. Br J Clin Pharmacol. 2016;81:971\u20139. https:\/\/doi.org\/10.1111\/bcp.12855.","journal-title":"Br J Clin Pharmacol"},{"key":"2697_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-10641-x","volume":"12","author":"T Kitsuka","year":"2022","unstructured":"Kitsuka T, Shiraki A, Oyama JI, Nakagami H, Tanaka A, Node K. A novel soluble epoxide hydrolase vaccine protects murine cardiac muscle against myocardial infarction. Sci Rep. 2022;12:6923. https:\/\/doi.org\/10.1038\/s41598-022-10641-x.","journal-title":"Sci Rep"},{"key":"2697_CR9","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1161\/01.HYP.0000176237.74820.75","volume":"46","author":"JD Imig","year":"2005","unstructured":"Imig JD, Zhao X, Zaharis CZ, Olearczyk JJ, Pollock DM, Newman JW, et al. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension. 2005;46:975\u201381.","journal-title":"Hypertension"},{"key":"2697_CR10","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1042\/CS20110622","volume":"122","author":"J Neck\u00e1\u0159","year":"2012","unstructured":"Neck\u00e1\u0159 J, Kopkan L, Huskov\u00e1 Z, Kol\u00e1\u0159 F, Papou\u0161ek F, Kramer HJ, et al. Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido) cyclohexyl-oxy] benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension. Clin Sci. 2012;122:513\u201325. https:\/\/doi.org\/10.1042\/CS20110622.","journal-title":"Clin Sci"},{"key":"2697_CR11","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1161\/hy0202.103788","volume":"39","author":"JD Imig","year":"2002","unstructured":"Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension. 2002;39:690\u20134. https:\/\/doi.org\/10.1161\/hy0202.103788.","journal-title":"Hypertension"},{"key":"2697_CR12","doi-asserted-by":"publisher","first-page":"100667","DOI":"10.1016\/j.jbc.2021.100667","volume":"296","author":"J Luo","year":"2021","unstructured":"Luo J, Hu S, Fu M, Luo L, Li Y, Li W, et al. Inhibition of soluble epoxide hydrolase alleviates insulin resistance and hypertension via downregulation of SGLT2 in the mouse kidney. J Biol Chem. 2021;296:100667. https:\/\/doi.org\/10.1016\/j.jbc.2021.100667.","journal-title":"J Biol Chem"},{"key":"2697_CR13","doi-asserted-by":"publisher","first-page":"e94092","DOI":"10.1371\/journal.pone.0094092","volume":"9","author":"L Li","year":"2014","unstructured":"Li L, Li N, Pang W, Zhang X, Hammock BD, Ai D, et al. Opposite effects of gene deficiency and pharmacological inhibition of soluble epoxide hydrolase on cardiac fibrosis. PLoS ONE. 2014;9:e94092. https:\/\/doi.org\/10.1371\/journal.pone.0094092.","journal-title":"PLoS ONE"},{"key":"2697_CR14","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1161\/HYPERTENSIONAHA.109.140558","volume":"55","author":"Y Kanematsu","year":"2010","unstructured":"Kanematsu Y, Kanematsu M, Kurihara C, Tsou TL, Nuki Y, Liang EI, et al. Pharmacologically induced thoracic and abdominal aortic aneurysms in mice. Hypertension. 2010;55:1267\u201374. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.109.140558.","journal-title":"Hypertension"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02697-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02697-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02697-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:08:36Z","timestamp":1785881316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02697-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2697"],"URL":"https:\/\/doi.org\/10.1038\/s41440-026-02697-3","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}